Clinical Trial

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I study to evaluate the safety and tolerability of sacituzumab govitecan in combination with capecitabine for advanced gastrointestinal cancers after progression on standard therapy, and to assess correlation of outcomes with the biomarker Trop-2.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-10-02; most recent amendment 2025-12-12.
Status change: Not Yet Recruiting → Recruiting 2024-12-04
Trial Details
NCT Number NCT06065371
Lead Sponsor Henry Ford Health System
Collaborators: Gilead Sciences
Conditions Gastrointestinal Cancer
Enrollment 20 participants
Start Date 2024-11-20
Primary Completion 2026-12 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2025-12-19